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Summary.-Immune-suppressed mice carrying xenografts of several different
types of human germ-cell tumours were injected with a radiolabelled monoclonal
antibody (LICR LON/HT13) raised against membrane components of a human
germ-cell tumour (HX39). Subsequent assessment of radioactivity in excised organs
and tumours showed a selective accretion of antibody in the tumour. Quantitative
autoradiography supported the results of radiolocalization observed in vivo in
different tumours, and also showed that the antibody localized to viable tumour cells
and in close association with their cell membrane. The vascular architecture of
tumours was found to be an important factor governing antibody distribution. No
localization occurred with radiolabelled normal mouse IgG.
THE LOCALIZATION of animal and
human tumours in vivo has been demon-
strated by the use ofradiolabelled affinity-
purified conventional antibodies (Primus
et al., 1973; Mach et al., 1974, 1980;
Goldenberg etal., 1978) and, more recently,
by monoclonal antibodies (Ballou et al.,
1979). Preferential tumour uptake of the
antibody has been shown, either by
measuring tumour and normal-tissue
radioactivity after their removal from the
host, or by external photoscanning of
tumours in situ. However, there have been
few recent studies which examine the
histological distribution of antibody in
tumours in conjunction with its in vivo
localization (Ghose et al., 1 980; Koji et al.,
1980).
The aim of this study has been to
demonstrate by autoradiography (ARG)
the tumour-cell specificity of an anti-
tumour monoclonal antibody adminis-
tered parenterally, and to confirm histo-
logically that the in vivo localization,
observed and described recently in an
animal model of human tiimours
(Moshakis et al., 1981b), is due to antigen-
antibody interaction.
MATERIALS AND METHODS
A imonoclonal antibody, LICR LON/HT13.
was raised against cells from the cell line
HX39, established from an undifferenti-
ated human malignant teratoma (MTU)
xenografted in immune-suppressed mice
(Raghavan et al., 1981). In vitro testing by
immunofluorescence and cell-binding assay
showed strong binding of the antibody to the
tumour-cell membrane (> 104 ct/min/105
cells). Between 10 and 15 ,uCi of 1251-labelled
antibody (5[Ci/yug) was injected i.v. into
mice carrying the xenografted tumour, to-
gether with equal amounts of 1311-labelled
normal mouse IgG. The same antibody was
used for the in vivo and ARG study of
localization in other human germ-cell xeno-
grafts and non-germ-cell tumours (Table I).
At intervals of between 4 and 96 h after
injection, the animals were killed, and radio-
activity (1251 and 1311) of excised tumours
and normal tissues was counted in a dual-
channel, w%ell-type scintillation counter
(LKB-1280 ultra-gamnma). The preparation
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TABLE I. Human tumour xenografts
used for the ARG studies, in conjunction
with in vivo localization experiments
Tumour
HX39
HX112
HXIlI
HX53
HX57
HX99
XKI
Pathology
MTU* witlh yolk-sac elements
Yolk-sac carcinoma
MTU
Seminoma with yolk-sac elemeInts
Yolk-sac carcinoma
Breast adenocarcinoma
Renal adenocarcinoma
* MTU =malignant teratoma undifferentiated.
of the radioiodinated antibodies, the path-
ology of the tumours and the in vivo localiza-
tion experiments, have been described in
detail elsewhere (Moshakis et al., 1981b;
Monaghan et al., 1981; Raghavan et al., 1981).
Autoradiographs were made of histological
sections oftumours and organs excised during
the localization experiments; thus, the degree
ofantibody uptake ofeach tumour and organ
autoradiographed was known. The tumours
and organs were fixed and embedded in
paraffin. The loss of radioactivity during
fixation and processing was calculated by
measuring the radioactivity of representative
samples of the fixation and processing re-
agents. From the 3 fixatives used in pilot
experiments (neutral formol saline, Bouin's
solution and glutaraldehyde), formol saline
was found to cause the least loss of radio-
activity. This loss amounted to only 10%
with the monoclonal antibody, but was
30-40% with the normal mouse IgG.
Since the sections contained both 1251
(specific IgG) and 1311 (nonspecific IgG)
activity, they were left for 3-4 weeks before
being dipped in emulsion (Mahaley et al.,
1965), so that the decay of 1311 and the fac-
tors governing the efficiency of grain pro-
duction (Rogers, 1967) ensured that >95%
of the grains were due to the 1251-labelled
monoclonal antibody. Dewaxed sections were
dipped for 2 sec in photographic emulsion
(Ilford K5), maintained at 50°C and at a
dilution of 1:1 with distilled water. After the
slides had been dried for 30 min, they were
placed in light-tight boxes containing silica
gel and exposed at 4°C for between 3 days
and 5 weeks. Exposed slides were then
developed (Kodak D19) and fixed (12-05%
Amfix, May & Baker) for 5 min each. Initial
experiments enabled us to establish the ideal
fixation and developing conditions to give
the minimal background activity without
appreciable loss of grain formation in the
tissues.
Quantitative ARG was undertaken wvith 3
different xenografts, HX39, HX99 and
XK1 (Table I). after their host animal had
been injected with 15 tCi of 1251-labelled
monoclonal antibody. All tumours were
removed from the animals 24h after injec-
tion, and were of similar weights (12-1-15-6
mg). Formalin-fixed and paraffin-embedded
sections were dipped in emulsion, exposed for
5 weeks, developed, fixed and counter-
stained with haematoxylin and eosin. Dark-
field illumination was used to count grains in
10 random fields in 5 different tumours of
each type. Thus, the number ofcell-associated
grains in a total area of 56 x 103 tZm2 of each
section was counted. Background grains were
also counted in 10 fields in each section around
the tumour at a distance of 1 to 1 fields from
the tumour edge.
ARG was also performed with frozen sec-
tions of tumours. Animals were injected with
either 125L-labelled monoclonal antibody or
with 1251-labelled normal IgG. Cryostat-cut
sections were placed on slides, fixed in formol
saline for 5 min and washed for 5 min in
distilled water. They were then dipped in K5
photographic emulsion and processed as
described above. In conjunction with ARG of
tumours labelled in vivo, ARG was also per-
formed on tumours labelled in vitro. Frozen
sections of tumours from animals which had
received no radioactivity were fixed in formol
saline for 5 min, washed with 0.500 BSA in
PBSA and 100 ,ul (105 et/min) of 1251-labelled
antibody or 1251-labelled normal IgG was
placed over the sections and incubated for 1 h.
The slides were washed with 0.500 BSA in
PBSA and, after drying, were dipped in K5
photographic emulsion. Exposure in light-
tight boxes was for 2-48 h.
In all the experiments, all sets of ARGs
contained positive and negative chemo-
graphy control slides. All slides were ex-
amined under bright and dark-field illumina-
tion.
RESULTS
The cellular distribution of the mono-
clonal antibody after in vivo tumour
labelling exhibited 2 patterns: (a) an
intense subcapsular concentration of
grains at the periphery of the tumours
over viable tumour cells (Fig. 1), this
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FIG. 1.-ARGs of sections of the germ-cell tumou
antibody HT13 and showing its subcapsular d
illumination. x 220.
subcapsular collection of grains being
maintained wherever fibrous septa entered
the tumour mass from the periphery; and
(b) scattered groups of grains within the
tumour, mostly situated near blood
vessels. In both areas, antibody was in
close association with the cell membrane
of individual cells (Fig. 2a). Areas of
tumour necrosis and fibrosis were devoid
of antibody, as were normal mouse
tissues. The distribution of the antibody
in frozen sections oftumours was the same
as in conventional sections. Such frozen
sections of tumour labelled in vivo with
1251-normal mouse IgG showed no binding
of the IgG to the tumour cell (Fig. 2b). No
binding was also demonstrated with 1251-
labelled nonspecific monoclonal antibody
LICR-LON-FIB75, which was used in
latter experiments as an additional control
(Moshakis et al., 198lb).
ir HX39, labelled in vivo withi 1251-monoclonal
listribution. (a) Bright-field and (b) dark-field
ARGs of frozen sections of tumours
incubated in vitro with 12-51-labelled anti-
body showed intense activity associated
with all tumour cells, and had a uniform
distribution throughout the tumour (Fig.
3a). The antibody did not bind to fibrous
areas or areas of necrosis. In parallel,
sections of the same tumours treated with
125J-labelled normal mouse IgG showed
no binding to the tumour cells (Fig. 3b).
In relation to this, it was found in vivo
that when non-radiolabelled HT13 (100
/tg/animal) was injected simultaneously
with radiolabelled HT13, tumour localiza-
tion was abolished, indicating that the
cold antibody was blocking the tumour
antigenic sites, thus inhibiting tumour
uptake of further radiolabelled antibody.
In parallel experiments, such inhibition
was not observed when cold nonspecific
monoclonal F1B75 or cold mouse IgG
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FIG. 2. ARGs of sections of the germ-cell tumour HX39, labelled in vivo with (a) 1251-labelled
monoclonal antibody HT13 and showing its close association with the tumour-cell membrane, and
(b) 125I-labelled normal mouse IgG. x 745.
were used for blocking the antigen
(Moshakis et al., 1981b).
The cellular distribution of HT13 in
other germ-cell tumour xenografts was the
same as in the HX39 tumour, against
which the antibody was raised. There was
a generalized tendency for the antibody
to be segregated in the peripheral, more
vascular parts of the tumour and to avoid
the central, more necrotic areas. In HX53
(a "mixed" germ-cell tumour containing
solid seminoma areas and cystic yolk-sac
elements), ARG of in-vivo-labelled
tumours demonstrated that HT13 would
localize only in the cystic yolk-sac parts of
the tumour, and not in the seminoma
areas (Fig. 4). There was no detectable
difference in distribution of the antibody
between yolk sac and MTU elements when
the other germ-cell tumours were ex-
amined (HXIII, HX112, HX57), indi-
cating that both elements have the same
antigenic determinants for anitibody
localization. In the 2 human non-germ-
cell tumours examined by ARG, there was
no antibody binding in the breast adeno-
carcinoma (HX99), but there was strong
association of the antibody to viable
TABLE II.-Correlation of visual grain
count with degree of localization after i.v.
administration of l25I-labelled HT13 in
3 groups ofanimals carryinghistologically
different tumour xenografts
Absolute grain
counts*
Tumour Per field
XK1 37465+ 4531
HX391 10608 + 1683
HX99 1546+ 192
Per
Mm2
6-69
1-89
0-27
LIt
r -_
24 h 48 h 96 h
7-5 8-7 27-1
3-1 7-0 10-9
1-4 1-1 1-1
* Means+ s.d. of 10 fields of each tumour. Five
tumours of each type were examined.
t Localization Index was used in the in vivo
experiments to express degrees of localization and is
calculated as follows:
1251/1311 in tumour or organ 12251/1311 in blood.
W When equal amounts of 125I-labelled normal
mouse IgG were injected rather than HT13, the
absolute graii counts were 408+ 83/field anid 0-07/
ILm2.
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FiG. 3.-ARGs of cryostat-cut sections of the germ-cell tumour HX39, incubated in vitro with (a)
125I-labelled monoclonal antibody HT13, and (b) 125I-labelled normal mouse IgG. x 560 (dark-
field illumination).
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FIG. 4. ARG of sections of the "mixed" germ-cell tumour HX53, labelled in vivo with 1251-labelled
monoclonal antibody HT13. Grains (antibody) are concentrated in the cystic yolk-sac areas on
the left, as opposed to the solid seminoma areas on the right. x 650.V. 1(0SHAKIS, RI. A. J. AlclLHINNEY AND) A. Ml. NEVILLE
ttumoLur cells of the renal adenocarcinoma
(XK1). This tumour was the only one of
4 non-germ-cell tumours which showed
uptake of the antibody in vivo (Moshakis
etal., 1981b).
The amount ofantibody in the tumours,
as found from quantitative ARG, corre-
lated with the various degrees of localiza-
tion found in the in vivo experiments
(Table II). The absolute visual grain count
W1as calculated by subt-racting the back-
ground grains from the tumour grains in
each section.
When the chemography slides were
examined in each set of the ARCs
throughout the experiments, neither posi-
tive chemographic effects nor significant
latent-image fading were found.
I)SCUSSION
Loecalization of i.v. radiolabelled anti-
bodies to tumouirs has been studied in the
past either by external radio-imaging or by
measurement of tissue radioactivity by
means of scintillation counting. Such
studies, though important, have certain
limitations, however, inthat selective hom-
ingofthe antibody tothe tumours can only
be expressed as uptake in whole specimens
of normal organs and tumours. Demon-
stration ofthe binding ofthe injected anti-
body to the tumour antigen at cellular
level would strengthen any evidence of
selective tumour localization obtained
from simultaneous in vivo studies, especi-
ally when new reagents such as mono-
clonal antibodies are being examined.
Our finding that the distribution of
monoclonal antibody after in vivo tumour-
labelling was the same in paraffin-em-
bedded and frozen sections of tumours,
confirmed that leaving conventional
tumour sections containing both 1251 and
1311 activity for 3-4 weeks before pro-
cessing produces ARGs with grain forma-
tion due to 1251 activity only (i.e. anti-
body). Thus, orthodox in vivo ARG(
methods canl be used successfully to
demonstrate radiolabelled monoclonal
antibodies in tumours. AWe have shown
that the mechanism of selective in vivo
localization of HT13 to the xenografted
tumour is related to antibody binding to
the membrane ofthe teratoma cells against
which the antibody was raised. The anti-
body was seen mostly in areas of high
vascularity, and therefore it appears that
vascular anatomy of tumours has an
important role in determining the access
of the antibody to the cell surface. The
absence of antibody from areas of viable
tumour, especially away from the peri-
phery, is most probably due to the poor
blood sppply in such areas, rather than to
the absence of antigen, since ARG of
tumour sections incubated with antibody
in vitro revealed that antigen was present
in all tumour cells.
The distribution of the antibody in the
other germ-cell tumours was the same as
in HX39, indicating that the mechanism
oflocalization was similar, and that all the
germ-cell tumours examined to date shared
the same antigenic determinant. Although
the antibody did not localize in non-germ-
cell tumours such as breast adenocarcin-
oma, bronchial adenocarcinoma and a
squamous-cell carcinoma (Moshakis et al.,
1981b), a high degree of localization was
found in a renal adenocarcinoma. The
cellular distribution of the injected anti-
body was the same as in the germ-cell
tumours, suggesting that this tumour type
can also express the same antigenic
determinant.
It is interesting that similar in vrio
experiments performed with convention-
ally raised antibodies to CEA for the
localization of human breast-tumour
xenografts (Moshakis et al., 1981a) demon-
strated that the injected anti-CEA bound
mostly to the CEA in the extracellular
tumour space, and not to the CEA on the
cell membrane (work in progress). How-
ever, more work is required to determine
whether this is one of the factors respons-
ible for the apparent superiority of mono-
clonal over conventional antibodies in
tumour localization, as seen by us and
others (Ballou et al., 1979).
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